☆
Watchlist
Log in
Sign-up
Atomo Diagnostics Ltd (at1) Logo

Atomo Diagnostics Ltd (AT1)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

AT1 Chart

Snapshot

AT1's Principal Activity is the development and sale of medical devices.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -15.78%
vs ASX 200 (1yr) -24.58%

Size

Market Capitalisation
ASX Rank 1,109 of 2,400
Sector Rank 95 of 207

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies VLS / IIQ / BD1
EPS -$0.011
DPS $0.00
NTA per share $0.05

Broker Consensus

AT1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Atomo Diagnostics Limited (AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Leichhardt NSW 2040
Website www.atomodiagnostics.com
Registry Link Market Services
Auditor BDO Audit Pty Ltd
Date Listed 16 Apr 2020

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Tharun Kuppanda Company Secretary Jan 2022
Ms Deborah Neff Non-Executive Director Sep 2021

Ms Deborah Neff

Non-Executive Director

Ms Neff has experience in building businesses and product commercialization in life sciences industry. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013. Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas. Deborah's work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines. Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively. Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean's Leadership Council at the University. Deborah also completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
Ms Gillian Maria Nairn Company Secretary Feb 2020
Dr Curt Harold LaBelle Non-Executive Director Oct 2016

Dr Curt Harold LaBelle

Non-Executive Director

Dr LaBelle has been involved in the healthcare industry for over 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF), a social impact investment fund. He also serves as a Director on the Boards of Z Optics, Evenovia, Revelation Bio and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former Director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Currently, he is Director of Eyenovia Inc. (NASDAQ:EYEN). He is a member of the Risk committee.
Mr John Perry Keith Non-Executive Chairman,Non-Executive Director Dec 2011

Mr John Perry Keith

Non-Executive Chairman,Non-Executive Director

Mr Keith is a Managing Director of BNP Paribas and its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the Boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is a member of the Risk, People and Culture committee.
Mr John Michael Kelly Founder,Chief Executive Officer,Managing Director Apr 2010

Mr John Michael Kelly

Founder,Chief Executive Officer,Managing Director

Mr Kelly has more than 20 years of experience in developing and commercialising medical devices to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the ground-breaking Mirage Swift and Activa mask systems.

Dr Paul Alexander Kasian Non-Executive Director N/A

Dr Paul Alexander Kasian

Non-Executive Director

Dr Kasian is an experienced Executive Director with experience in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Non-Executive Director of Zucero Therapeutics Ltd and and Eco Systems Ltd. He is chair of the Risk committee.
William Souter Chief Financial Officer N/A
Mark Smith Chief Operating Officer N/A
Show All

Director Transactions

AT1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
03/11/21 John Kelly Expiry 666,667 $0.265 $176,666 Options expired
03/11/21 John Kelly Issued 333,333 $0.265 $88,333 Issue of options
03/11/21 John Kelly Sell +1,040,000 $0.276 ($286,896) As advised by the company
09/04/21 Curt LaBelle Buy +960,000 $0.156 $150,000 Exercise of options
09/04/21 Curt LaBelle Exercise 960,000 $0.156 $150,000 Exercise of options
09/04/21 Curt LaBelle Buy +240,000 $0.156 $37,500 Exercise of options
09/04/21 Curt LaBelle Exercise 240,000 $0.156 $37,500 Exercise of options
Show All

Director Interests

The current holdings of AT1 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
John Kelly 03/11/2021 7,370,248 65,120,000 1,666,666 N/A
Deborah Neff 15/09/2021 0 N/A N/A N/A
Curt LaBelle 30/06/2021 240,000 64,811,280 2,400,000 N/A
John Keith 30/06/2021 3,261,056 N/A 3,600,000 N/A
Paul Kasian 30/06/2021 N/A 100,000 N/A N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 27, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dalraida Holdings Pty Limited 66,160,000 11.64%
Global Health Investment Fund I LLC 64,811,280 11.40%
HSBC Custody Nominees (Australia) Limited 46,427,252 8.17%
Walker Group Holdings Pty Ltd 37,660,718 6.62%
National Nominees Limited 22,976,845 4.04%
J P Morgan Nominees Australia Pty Limited 14,258,766 2.51%
Grand Challenges Canada 11,390,824 2.00%
Liverbird Pty Ltd 10,931,653 1.92%
I D E Pty Ltd 9,032,248 1.59%
Mark Andrew Smith 7,790,224 1.30%
John Michael Kelly 7,370,248 1.30%
Leo James Lynch & Judith Anne Beswick 7,321,121 1.29%
Mr Ian Fredrick Johnson 6,079,560 1.07%
Ruth Karen Devney 5,626,408 0.99%
Citicorp Nominees Pty Limited 5,373,057 0.94%
Bosana Nominees Pty Ltd 5,081,496 0.89%
Sokolov Pty Ltd 4,500,000 0.79%
Poul Damgaard Hansen 4,340,184 0.76%
Miss Lisa Marie Mackenzie 3,351,968 0.59%
Alex Griffiths 3,283,872 0.58%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 328 3,489 1,533 2,718 386 8,454

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Walker Group Holdings Pty Limited 27/08/2021 37,660,718 6.70
John Kelly 27/08/2021 73,530,248 13.11
Global Health Investment Fund I LLC 27/08/2021 63,851,280 11.38
Ellerston Capital Limited 25/11/2021 49,329,568 8.68

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
25-11-21 Ellerston Capital Limited 7,743,283 7.31 8.68
15-09-21 Ellerston Capital Limited 7,211,285 6.13 7.31
10-09-21 SG Hiscock and Company Limited 20,909,532 -- 5.12
29-06-21 Perennial Value Management Limited 7,334,006 6.35 7.56

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
14-09-21 SG Hiscock and Company Limited 20,909,532 5.12 --
09-08-21 Perennial Value Management Limited 42,962,957 7.56 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.34 30 June
AT1 Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.